Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS

[1] Cheson BD(1976)Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment Chin Med J 2 263-272

[2] Bennett JM(2003)Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 4642-4649

[3] Kopecky KJ(2006)Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 419-425

[4] Cheson BD(1987)Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy Am J Clin Pathol 87 180-186

[5] Greenberg PL(2009)Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 223-232

[6] Bennett JM(2005)Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) Leukemia 19 2223-2231

[7] Delacretaz F(1997)International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079-2088

[8] Schmidt PM(2006)Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia Leukemia 20 1361-1367

[9] Piguet D(1989)Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia Cancer 63 813-817

[10] Bachmann F(2006)Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794-1803

[1] Cheson BD(1976)Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment Chin Med J 2 263-272

[2] Bennett JM(2003)Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 4642-4649

[3] Kopecky KJ(2006)Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 419-425

[4] Cheson BD(1987)Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy Am J Clin Pathol 87 180-186

[5] Greenberg PL(2009)Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 223-232

[6] Bennett JM(2005)Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) Leukemia 19 2223-2231

[7] Delacretaz F(1997)International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079-2088

[8] Schmidt PM(2006)Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia Leukemia 20 1361-1367

[9] Piguet D(1989)Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia Cancer 63 813-817

[10] Bachmann F(2006)Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794-1803